Assembly Biosciences, Inc.
NASDAQ:ASMBBiotechnology
+$0.16 today
- Market cap
- $458.48M
- Beta
- 1.08
- P/E (TTM)
- -64.4
- EPS (TTM)
- -$0.38
Volume 0.49M
Average 0.17M
ASMB Tax Payables
Taxes owed to authorities that have not yet been paid.
Assembly Biosciences, Inc.NASDAQ: ASMB
Tax Payables · Q1 FY2026 · quarter ended Mar 2026
Tax payables remains negative
Q1 FY2026 tax payables was $0, compared with $0 a year earlier.
Context
- Tax payables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Tax payables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Tax Payables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Tax Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Tax Payables vs competitors
How ASMB compares with its peers on the latest reported figures
- ASMB's Mar 2026 tax payables of $0 is the highest of the 6 companies compared; the peer median is $0.
- Tax payables amounts to 0.0% of total assets for ASMB, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ASMB) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 45.63M | 52.42M | 19.84M | 38.34M | 58.45M |
| Short-term Investments | 101M | 39.19M | 110.41M | 73.74M | 189.66M |
| Net Receivables | 336K | 944K | 43K | 400K | 974K |
| Inventory | 0 | 0 | (3.2M) | 0 | 0 |
| Other Current Assets | 0 | 300K | 3.5M | 3.02M | 5.47M |
| Total Current Assets | 154.2M | 96.97M | 133.79M | 115.5M | 254.55M |
| Property, Plant & Equipment (Net) | 7.18M | 3.94M | 2.72M | 3.35M | 2.73M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 27.97M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.7M | 889K | 312K | 312K | 312K |
| Total Non-current Assets | 36.86M | 4.83M | 3.04M | 3.67M | 3.04M |
| Total Assets | 191.06M | 101.79M | 136.82M | 119.17M | 257.59M |
| Account Payables | 2.66M | 2.49M | 461K | 585K | 1.17M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 30.92M | 37.62M | 36.9M |
| Other Current Liabilities | 6.43M | 599K | 1.15M | 6.48M | 7.52M |
| Total Current Liabilities | 16.07M | 16.3M | 39.23M | 47.8M | 48.78M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 2.73M | 0 | 55.38M | 0 | 0 |
| Other Non-current Liabilities | 0 | 2.73M | 0 | 35.38M | 0 |
| Total Non-current Liabilities | 6.06M | 2.83M | 56.5M | 38.01M | 2.06M |
| Total Liabilities | 22.13M | 19.13M | 95.73M | 85.81M | 50.84M |
| Common Stock | 48K | 4K | 5K | 7K | 16K |
| Retained Earnings | (631.43M) | (724.52M) | (785.75M) | (825.93M) | (832.05M) |
| Accumulated OCI | (419K) | (803K) | (81K) | (211K) | (41K) |
| Other Stockholders Equity | 0 | (1) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 168.93M | 82.66M | 41.1M | 33.36M | 206.75M |
| Total Debt | 6.48M | 3.47M | 2.34M | 3.09M | 2.63M |
| Net Debt | (39.15M) | (48.95M) | (17.5M) | (35.26M) | (55.82M) |
Assembly Biosciences, Inc.
NASDAQ:ASMB
Intrinsic Alpha fair value
Locked
Current Price
$22.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.